Inactive Instrument

Analyst Reco. Gracell Biotechnologies Inc.

Equities

GRCL

US38406L1035

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

Stifel Downgrades Gracell Biotechnologies to Hold From Buy, Trims Price Target to $10.25 From $11	Feb. 22	MT
Wells Fargo Downgrades Gracell Biotechnologies to Equalweight From Overweight, $10 Price Target	Dec. 27	MT
Stocks hold onto gains amid US rate cut hopes	Dec. 27	AN
Year-end rate-cut optimism, miners push UK stocks higher	Dec. 27	RE
Piper Sandler Downgrades Gracell Biotechnologies to Neutral From Overweight, Raises Price Target to $10 From $9	Dec. 27	MT
Wall Street ends higher in final stretch of 2023	Dec. 26	RE
Wall Street gains on final stretch of 2023, rate cuts in view	Dec. 26	RE
Jefferies Downgrades Gracell Biotechnologies to Hold From Buy, Raises Price Target to $11.50 From $11	Dec. 26	MT
BTIG Research Downgrades Gracell Biotechnologies to Neutral From Buy	Dec. 26	MT
Wells Fargo Raises Gracell Biotechnologies' Price Target to $10 From $7, Maintains Overweight Rating	Dec. 26	MT
HC Wainwright Downgrades Gracell Biotechnologies to Neutral From Buy, Adjusts Price Target to $10 From $13	Dec. 26	MT
Wall Street rises as rate-cut bets strengthen	Dec. 26	RE
Expected Rate Cuts Continue to Buoy Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday	Dec. 26	MT
Futures edge higher amid strengthening rate cut bets	Dec. 26	RE
Evercore ISI Starts Gracell Biotechnologies With Outperform Rating	Nov. 27	MT
Stifel Starts Gracell Biotechnologies With Buy Rating, Price Target is $11	23-10-19	MT
Gracell Biotechnologies Reports Updated Clinical Data for Fastcar-T Gc012f for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate	23-09-27	CI
Citigroup Trims Gracell Biotechnologies Price Target to $11 From $12, Maintains Buy Rating	23-08-29	MT
HC Wainwright Adjusts Gracell Biotechnologies' Price Target to $13 From $12, Keeps Buy Rating	23-08-14	MT
BTIG Adjusts Price Target on Gracell Biotechnologies to $20 From $18, Maintains Buy Rating	23-06-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Gracell Biotechnologies Inc.

Equities

GRCL

US38406L1035

Analyst Reco.

Filters